Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47 per cent more weight than those who were given ...

Eli Lilly & Co. Inc.’s stock LLY rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more ...

Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk's Wegovy showed an average weight loss of 20.2% ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...